Abbott (NYSE: ABT) announced it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System,(1) the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers. The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months.
According to the American Diabetes Association (ADA), approximately 25.8 million people in the United States have diabetes,(2) and of those, many require insulin to manage their condition. The FreeStyle InsuLinx System is the newest addition to Abbott's portfolio of glucose monitoring systems and is designed to use FreeStyle technology to help insulin-using patients monitor their blood glucose levels to allow them to more effectively manage their condition.
FDA Weighs Over-The-Counter Switch For Key Drugs by THE ASSOCIATED PRESS
text size A A A WASHINGTON March 7, 2012, 08:34 pm ET WASHINGTON (AP) — Some of the most widely used prescription drugs, including those to treat cholesterol and high blood pressure, could be available over the counter under a new proposal being weighed by government regulators.
Food and Drug Administration officials said Wednesday they are considering waiving prescription requirements for certain drugs used to treat ailments like diabetes, asthma and migraine. Driving the move is a wave of computer technology, including touch-screen kiosks found in pharmacies, designed to help patients self-diagnose common diseases.
FDA regulators told reporters that easing access to obtain certain medications could help address undertreated epidemics like diabetes. Of the more than 25 million Americans with diabetes, an estimated 7 million are not diagnosed and therefore do not receive treatment. Diabetes is a leading cause of heart disease and stroke.
"These are discussions that need to start happening as we think about people's health needs and how to improve access," said FDA Commissioner Dr. Margaret Hamburg.
DELRAY BEACH, Fla., March 5, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCBB:PSID.OB - News), a developer of medical technologies for diabetes management, announced today that it has finalized its first-in-class development of a fully synthetic glucose sensing system to measure glucose levels within the body for people with diabetes. PositiveID and its partner RECEPTORS LLC believe they are the first to develop a fully synthetic, stable, sensitive, selective sensing system that is responsive to glucose in human plasma, which is considered to be a critical step in the development of an artificial pancreas.
Diabetes Unscripted is about real life caregivers who share their stories about being a caregiver for someone living with diabetes. I became interested in pursuing the idea of researching and sharing caregiver stories because my own family has been impacted by type II diabetes. My mom is the primary caregiver for my dad and has looked after him for many years. I was inspired by my mother’s compassion and ability to care for my dad but it hasn’t always been easy.
Medtronic Insulin Pumps Vulnerable, Says Hacker Mar. 1, 2012 - March 1 (Bloomberg) -- Some Medtronic Inc. insulin pumps are vulnerable to a hacking attack that could let someone break into the devices from hundreds of feet away, disable security alarms and dump insulin directly into diabetics' bloodstreams, according to a computer-security researcher at McAfee Inc. Jon Erlichman reports on Bloomberg Television's "InsideTrack." (Source: Bloomberg) (Bloomberg) Video
Researchers from Denver Health and Hospital Authority, a medical school, found that patients with diabetes who received text message reminders and prompts throughout the week reported increased accountability, social support, and awareness of health information. The Researchers found that 79 percent of the participants responded to more than 50 percent of the prompts, according to the study’s results which were recently published in the American Journal of Managed Care. About 66 percent provided glucose readings when their care provided prompted them by text message, compared to the 12 percent that provided readings at two previous clinic visits.
LCT Half Yearly Report period ended 31 December 2011 28 February 2012: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), today announced the half yearly report for the six months ended 31 December 2011. The report is attached.
The consolidated operating profit after income tax for the period 1 July to 31 December 2012 was $8.1 million (2010 loss $4.3m). This turnaround is primarily due to an $11.2 million gain on sale of DIABECELL® intellectual property to Diatranz Otsuka Limited (DOL), a 50% owned company, and $0.9 million of services fees charged to DOL from 1 November.
During the six months ended 31 December 2011 the company implanted 4 patients in Argentina with DIABECELL, continued the primate study of NTCELL for the treatment of Parkinson's disease and provided services to DOL. Services fees were $0.9m (2010: $0.2m) and grant income was $0.4m (2010: $0.8m). Cost of services was $0.8 m (2010: $0.0m), research and development costs were $1.8m in the period (2010: $2.8m), for the supply of DIABECELL for the clinical trial in Argentina and preclinical studies of NTCELL. A foreign exchange loss of $0.1m was reported compared to a loss of $0.6m last year.
As at 31 December 2011 net assets were $15.0m compared to $4.2m at 31 December 2010 and $6.8m as at 30 June 2011. Cash and cash equivalents at 31 December 2011 decreased to $2.5m (30 June 2011 $4.5m).
On 1 November 2011 the company settled the formation of a 50/50 company Diatranz Otsuka Limited with Otsuka Pharmaceutical Factory, Inc. (OPF), to accelerate the commercialisation of DIABECELL. LCT sold DIABECELL assets to DOL for $25m of shares and OPF invested $25m of cash in DOL. LCT provides research and development and administrative services to DOL at commercial rates and retains access to the facilities and designated pathogen free pigs for products other than diabetes.
Musician and philanthropist, Bret Michaels announced today that he will issue a fitness challenge to the public that will "Rock The World." Michaels joins the Champions of Health on GoodChime! to foster greater...
Pharmaceutical Industry | NEWS | General | Novo Nordisk files another Lantus rival in Japan - Danish pharma company's combination product - known as DegludecPlus in Europe – submitted to regulators | PMLiVE...
What we thought was going to be a routine doctor’s visit turned out to be life-changing......The visit felt perfunctory, just over-attentive parents worrying a little too much.
Turns out we hadn’t been worrying enough.
After a urine test and a finger prick, the doctor came back with the diagnosis: He had type-1 diabetes. She instructed us to get to the emergency room as fast as possible and to be ready to spend the entire weekend at the hospital. There was no time to go home to pick up a bag. (There is the possibility he could have been in diabetic ketoacidosis a state in which the body starts breaking down its own fat and producing ketones. This can alter the acidity of the blood and is potentially life threatening depending on the pH.)
Biotech veteran will expand scope of innovative type 1 diabetes organization’s initiative
March 06, 2012 07:03 AM Eastern Time BOSTON--(EON: Enhanced Online News)--The T1D Exchange, a not-for-profit organization accelerating the discovery of new approaches to type 1 diabetes research and treatment, announced today the hire of Imran Nasrullah, MS, JD, as the first head of strategic alliances. Mr. Nasrullah was previously Chief Business Officer of the Massachusetts Biotechnology Council. In his new role at the T1D Exchange, Mr. Nasrullah will develop and maintain partnerships with industry, academic and not-for-profit partners. The T1D Exchange was designed to connect the disparate stakeholders in the type 1 diabetes community—individuals with type 1 diabetes, caregivers, clinicians, researchers and industry partners—by combining the critical components of traditional clinical research with the expanding fields of health information technology and social networking. It currently consists of a biobank, clinical registry, and Glu, an online social network for people with type 1 diabetes. The T1D Exchange was founded in 2010 through a grant from The Leona M. and Harry B. Helmsley Charitable Trust’s Type 1 Diabetes Program....
First Aid Kit's Klara and Johanna Söderberg have been making music together as a duo since 2007, and have been sisters for somewhat longer.Mixing a naturalistic, folk roots sound with a country twang, the pair's music creates a world somewhere...
Despite starting their musical career while still schoolgirls, First Aid Kit's music has always displayed a lyrical maturity - something they partly credit to a rather unusual inspiration:
K - "I'm allergic to gluten."
J - "And you have diabetes!"
K - "Yep, I have diabetes too - I'm a sick kid! I discovered I was diabetic at nine and allergic to gluten about ten, they're kind of connected."
J - "I think it's affected you as a person, it's made you very responsible."
K - "Well you have to be. When you're 9 years old it's a big thing when suddenly everything you do you have to think about first - you can't just eat that candy you want anymore, you have to take your insulin shot. You have to learn to take care of yourself otherwise you feel like shit."
J - "I think that made you a lot more mature, and that's why you write such good lyrics."
K - "Yes! It's all because of diabetes!"
J - "And that's why we're called... First Aid Kit!"
Some Medtronic Inc. insulin pumps are vulnerable to a hacking attack that could let someone break into the devices from hundreds of feet away, disable security alarms and dump insulin directly into diabetics’ bloodstreams, according to a...
MIAMI, March 1, 2012 /PRNewswire-USNewswire/ -- Scientists at the Diabetes Research Institute have developed a revolutionary technique to provide critical oxygen for maintaining the survival of insulin-producing cells. This is the first time that scientists have been able to successfully deliver oxygen locally to beta cells using a biomaterial. The results of the study, which represents a major step toward the goal of developing an alternative site to house insulin-producing cells, were just published in the prestigious journal Proceedings of the National Academy of Science (PNAS).
A new study suggests that people who take sleeping pills are more likely to die within a couple of years than those who don’t, though it doesn’t prove that the pills caused people to die before they otherwise would have — and outside experts say patients shouldn’t panic and toss their medications.
The study is published in BMJ Open, an open-access online journal. (Here’s its open peer-review policy.)
The Food and Drug Administration (FDA) added new safety warnings to cholesterol-reducing statin drugs on Wednesday, noting increased risks of Type 2 diabetes and memory loss for patients who take the medications.